242 related articles for article (PubMed ID: 20028750)
1. Association of epidermal growth factor receptor polymorphism, skin toxicity, and outcome in patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment.
Klinghammer K; Knödler M; Schmittel A; Budach V; Keilholz U; Tinhofer I
Clin Cancer Res; 2010 Jan; 16(1):304-10. PubMed ID: 20028750
[TBL] [Abstract][Full Text] [Related]
2. Expression of amphiregulin and EGFRvIII affect outcome of patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment.
Tinhofer I; Klinghammer K; Weichert W; Knödler M; Stenzinger A; Gauler T; Budach V; Keilholz U
Clin Cancer Res; 2011 Aug; 17(15):5197-204. PubMed ID: 21653686
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of cetuximab in combination with docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck after platinum-containing therapy: a multicenter study of the Arbeitsgemeinschaft Internistische Onkologie.
Knoedler M; Gauler TC; Gruenwald V; Matzdorff A; Schroeder M; Dietz A; Jordan WO; Arnold D; Hennemann B; Hofele C; Weissinger F; Eberhardt W; Keilholz U
Oncology; 2013; 84(5):284-9. PubMed ID: 23445718
[TBL] [Abstract][Full Text] [Related]
4. EGFR intron 1 dinucleotide repeat polymorphism is associated with the occurrence of skin rash with gefitinib treatment.
Huang CL; Yang CH; Yeh KH; Hu FC; Chen KY; Shih JY; Lin ZZ; Yu CJ; Cheng AL; Yang PC
Lung Cancer; 2009 Jun; 64(3):346-51. PubMed ID: 18995924
[TBL] [Abstract][Full Text] [Related]
5. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck.
Herbst RS; Arquette M; Shin DM; Dicke K; Vokes EE; Azarnia N; Hong WK; Kies MS
J Clin Oncol; 2005 Aug; 23(24):5578-87. PubMed ID: 16009949
[TBL] [Abstract][Full Text] [Related]
6. Polymorphisms of the epidermal growth factor receptor (EGFR) and survival in patients with advanced cancer of the head and neck (HNSCC).
Stoehlmacher-Williams J; Obermann L; Ehninger G; Goekkurt E
Anticancer Res; 2012 Feb; 32(2):421-5. PubMed ID: 22287728
[TBL] [Abstract][Full Text] [Related]
7. Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial.
Rivera F; García-Castaño A; Vega N; Vega-Villegas ME; Gutiérrez-Sanz L
Expert Rev Anticancer Ther; 2009 Oct; 9(10):1421-8. PubMed ID: 19828002
[TBL] [Abstract][Full Text] [Related]
8. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm.
Pfister DG; Su YB; Kraus DH; Wolden SL; Lis E; Aliff TB; Zahalsky AJ; Lake S; Needle MN; Shaha AR; Shah JP; Zelefsky MJ
J Clin Oncol; 2006 Mar; 24(7):1072-8. PubMed ID: 16505426
[TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor receptor intron 1 CA dinucleotide repeat polymorphism and survival of advanced gastric cancer patients treated with cetuximab plus modified FOLFOX6.
Han SW; Oh DY; Im SA; Park SR; Lee KW; Song HS; Lee NS; Lee KH; Choi IS; Lee MH; Kim MA; Kim WH; Bang YJ; Kim TY
Cancer Sci; 2010 Mar; 101(3):793-9. PubMed ID: 20047592
[TBL] [Abstract][Full Text] [Related]
10. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy.
Vermorken JB; Trigo J; Hitt R; Koralewski P; Diaz-Rubio E; Rolland F; Knecht R; Amellal N; Schueler A; Baselga J
J Clin Oncol; 2007 Jun; 25(16):2171-7. PubMed ID: 17538161
[TBL] [Abstract][Full Text] [Related]
11. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study.
Burtness B; Goldwasser MA; Flood W; Mattar B; Forastiere AA;
J Clin Oncol; 2005 Dec; 23(34):8646-54. PubMed ID: 16314626
[TBL] [Abstract][Full Text] [Related]
12. Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial.
Martins RG; Parvathaneni U; Bauman JE; Sharma AK; Raez LE; Papagikos MA; Yunus F; Kurland BF; Eaton KD; Liao JJ; Mendez E; Futran N; Wang DX; Chai X; Wallace SG; Austin M; Schmidt R; Hayes DN
J Clin Oncol; 2013 Apr; 31(11):1415-21. PubMed ID: 23460709
[TBL] [Abstract][Full Text] [Related]
13. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck.
Baselga J; Trigo JM; Bourhis J; Tortochaux J; Cortés-Funes H; Hitt R; Gascón P; Amellal N; Harstrick A; Eckardt A
J Clin Oncol; 2005 Aug; 23(24):5568-77. PubMed ID: 16009950
[TBL] [Abstract][Full Text] [Related]
14. A retrospective, multicenter study of the tolerance of induction chemotherapy with docetaxel, Cisplatin, and 5-Fluorouracil followed by radiotherapy with concomitant cetuximab in 46 cases of squamous cell carcinoma of the head and neck.
Buiret G; Combe C; Favrel V; Pommier P; Martin L; Ecochard R; Fayette J; Tartas S; Ramade A; Céruse P
Int J Radiat Oncol Biol Phys; 2010 Jun; 77(2):430-7. PubMed ID: 19775831
[TBL] [Abstract][Full Text] [Related]
15. Anti-EGFR-targeting agents in recurrent or metastatic head and neck carcinoma: a meta-analysis.
Petrelli F; Barni S
Head Neck; 2012 Nov; 34(11):1657-64. PubMed ID: 21953841
[TBL] [Abstract][Full Text] [Related]
16. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.
Sok JC; Coppelli FM; Thomas SM; Lango MN; Xi S; Hunt JL; Freilino ML; Graner MW; Wikstrand CJ; Bigner DD; Gooding WE; Furnari FB; Grandis JR
Clin Cancer Res; 2006 Sep; 12(17):5064-73. PubMed ID: 16951222
[TBL] [Abstract][Full Text] [Related]
17. Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab.
Lurje G; Nagashima F; Zhang W; Yang D; Chang HM; Gordon MA; El-Khoueiry A; Husain H; Wilson PM; Ladner RD; Mauro DJ; Langer C; Rowinsky EK; Lenz HJ
Clin Cancer Res; 2008 Dec; 14(23):7884-95. PubMed ID: 19047118
[TBL] [Abstract][Full Text] [Related]
18. Association between EGFR gene polymorphisms, skin rash and response to anti-EGFR therapy in metastatic colorectal cancer patients.
Jaka A; Gutiérrez-Rivera A; Ormaechea N; Blanco J; La Casta A; Sarasqueta C; Izeta A; Tuneu A
Exp Dermatol; 2014 Oct; 23(10):751-3. PubMed ID: 25039761
[TBL] [Abstract][Full Text] [Related]
19. Paclitaxel and cetuximab combination efficiency after the failure of a platinum-based chemotherapy in recurrent/metastatic head and neck squamous cell carcinoma.
Péron J; Ceruse P; Lavergne E; Buiret G; Pham BN; Chabaud S; Favier B; Girodet D; Zrounba P; Ramade A; Fayette J
Anticancer Drugs; 2012 Oct; 23(9):996-1001. PubMed ID: 22643048
[TBL] [Abstract][Full Text] [Related]
20. Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Bourhis J; Rivera F; Mesia R; Awada A; Geoffrois L; Borel C; Humblet Y; Lopez-Pousa A; Hitt R; Vega Villegas ME; Duck L; Rosine D; Amellal N; Schueler A; Harstrick A
J Clin Oncol; 2006 Jun; 24(18):2866-72. PubMed ID: 16717293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]